Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)?

Neurogastroenterology and Motility

Volumn 27, Issue 1, 2015, Pages 19-29

  Pinn, D M ^a   Aroniadis, O C ^b   Brandt, L J ^b  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Fecal microbiota transplantation; Functional gastrointestinal disorders; Intestinal microbiota; Irritable bowel syndrome

Indexed keywords

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DONOR SELECTION; FECES; GASTROINTESTINAL DISEASES; HUMANS; INTESTINES; IRRITABLE BOWEL SYNDROME; MICROBIOLOGY; MICROBIOTA; TREATMENT OUTCOME;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DONOR SELECTION; FECES; GASTROINTESTINAL DISEASES; HUMANS; INTESTINES; IRRITABLE BOWEL SYNDROME; MICROBIOTA; TREATMENT OUTCOME;

EID: 84920100399     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12479     Document Type: Review

References (105)

1. Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking in the functional GI disorders: a population-based study. Am J Gastroenterol 2002; 97: 2290-9.
2. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-90.
3. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-21.
4. Saito YA, Schoenfeld P, Locke GRI. The epidemiology of irritable bowel syndrome in North America: systemic review. Am J Gastroenterol 2002; 97: 1910-5.
5. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119: 654-60.
6. Simrén M, Svedlund J. Health-related quality of life in patients attending a gastroenterology outpatient clinic: functional disorders versus organic diseases. Clin Gastroenterol Hepatol 2006; 4: 187-95.
7. Bengtson M-B, Rønning T, Vatn MH, Harris JR. Irritable bowel syndrome in twins: genes and environment. Gut 2006; 55: 1754-9.
8. Öhman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7: 163-73.
9. Gunnarsson J, Simren M. Peripheral factors in the pathophysiology of irritable bowel syndrome. Dig Liver Dis 2009; 41: 788-93.
10. Stecher B, Chaffron S, Käppeli R, Hapfelmeier S, Freedrich S, Weber TC, Kirundi J, Suar M et al. Like will to like: abundances of closely related species can predict susceptibility to intestinal colonization by pathogenic and commensal bacteria. PLoS Pathog 2010; 6: e1000711.
11. Iwai H, Ishihara Y, Yamanaka J, Ito T. Effects of bacterial flora on cecal size and transit rate of intestinal contents in mice. Jpn J Exp Med 1973; 43: 297-305.
12. DuPont AW, Jiang ZD, Harold SA, Snyder N, Galler GW, Garcia-Torres F, DuPont HL. Motility abnormalities in irritable bowel syndrome. Digestion 2014; 89: 119-23.
13. Mete R, Tulubas F, Oran M, Yilmaz A, Avci BA, Yildiz K, Turan CB, Gurel A. The role of oxidants and reactive nitrogen species in irritable bowel syndrome: a potential etiological explanation. Med Sci Monit. 2013; 19: 762-6.
14. Husebye E, Hellström PM, Sundler F, Chen J, Midtvedt T. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am J Physiol Gastrointest Liver Physiol 2001; 280: G368-80.
15. Barbara G, Vallance BA, Collins SM. Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. Gastroenterology 1997; 113: 1224-32.
16. Karczewski J, Poniedzialek B, Adamski Z, Rzymski P. The effects of the microbiota on the host immune system. Autoimmunity. 2014; 14: 1-11.
17. Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol 2004; 4: 478-85.
18. Macpherson AJ, Hunziker L, McCoy K, Lamarre A. IgA responses in the intestinal mucosa against pathogenic and non-pathogenic microorganisms. Microbes Infect 2001; 3: 1021-35.
19. Helgeland L, Vaage JT, Rolstad B, Halstensen TS, Midtvedt T, Brandtzaeg P. Regional phenotypic specialization of intraepithelial lymphocytes in the rat intestine does not depend on microbial colonization. Scand J Immunol 1997; 46: 349-57.
20. Falk PG, Hooper LV, Midtvedt T, Gordon JI. Creating and maintaining the gastrointestinal ecosystem: what we know and need to know from gnotobiology. Microbiol Mol Biol Rev. 1998; 62: 1157-70.
21. Lundin A, Bok CM, Aronsson L, Björkholm B, Gustafsson JA, Pott S, Arulampalam V, Hibberd M et al. Gut flora, Toll-like receptors and nuclear receptors: a tripartite communication that tunes innate immunity in large intestine. Cell Microbiol. 2008; 10: 1093-103.
22. Bercík P, Wang L, Verdú EF, Mao YK, Blennerhassett P, Khan WI, Kean I, Tougas G et al. Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterology 2004; 127: 179-87.
23. Hod K, Dickman R, Sperber A, Melamed S, Dekel R, Ron Y, Halpern Z, Berliner S et al. Assessment of high-sensitivity CRP as a marker of micro-inflammation in irritable bowel syndrome. Neurogastroenterol Motil 2011; 23: 1105-10.
24. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-83.
25. Brint EK, Macsharry J, Fanning A, Shanahan F, Quigley EM. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol. 2011; 106: 329-36.
26. Belmonte L, Beutheu Youmba S, Bertiaux-Vandaële N, Antonietti M, Lecleire S, Zalar A, Gourcerol G, Leroi AM et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS One 2012; 7: e42777.
27. Gwee KA, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, McKendrick MW, Moochhala SM. Increased rectal mucosal expression of interleukin 1β in recently acquired post-infectious irritable bowel syndrome. Gut 2003; 52: 523-6.
28. O'Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, O'Morain CA. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000; 12: 449-57.
29. Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, Martínez C, Casellas F et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56: 203-9.
30. Buhner S, Li Q, Vignali S, Barbara G, De Giorgio R, Stanghellini V, Cremon C, Zeller F. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009; 137: 1425-34.
31. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702.
32. Piche T, Barbara G, Aubert P, Bruley des Varannes S, Dainese R, Nano JL, Cremon C, Stanghellini V et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58: 196-201.
33. Langhorst J, Junge A, Rueffer A, Wehkamp J, Foell D, Michalsen A, Musial F, Dobos GJ. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 2009; 104: 404-10.
34. Bonfrate L, Tack J, Grattagliano I, Cuomo R, Portincasa P. Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options. Scand J Gastroenterol. 2013; 48: 995-1009.
35. Ohman L, Simrén M. Intestinal microbiota and its role in irritable bowel syndrome (IBS). Curr Gastroenterol Rep. 2013; 15: 323.
36. Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain.Nat Rev Microbiol 2012; 10: 735-42.
37. Mayer EA. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci 2011; 12: 453-66.
38. Locke GR 3rd, Weaver AL, Melton LJ 3rd, Talley NJ. Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study. Am J Gastroenterol. 2004; 99: 350-7.
39. Murray CD, Flynn J, Ratcliffe L, Jacyna MR, Kamm MA, Emmanuel AV.Effect of acute physical and psychological stress on gut autonomic innervation in irritable bowel syndrome.Gastroenterology 2004 127: 1695-703.
40. O'Mahony SM, Marchesi JR, Cully P, Codling C, Ceolho AM, Quigley EM, Cryan JF, Dinan TG.Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses.Biol Psychiatry 2009;65:263-7.
41. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-11.
42. Lyte M, Varcoe JJ, Bailey MT. Anxiogenic effect of subclinical bacterial infection in mice in the absence of overt immune activation. Physiol Behav 1998; 65: 63-8.
43. Goehler LE, Gaykema RP, Opitz N, Reddaway R, Badr N, Lyte M. Activation in vagal afferents and central autonomic pathways: early responses to intestinal infection with Campylobacter jejuni. Brain Behav Immun 2005; 19: 334-44.
44. Maxwell PR, Rink E, Kumar D, Mendall MA. Antibiotics increase functional abdominal symptoms. Am J Gastroenterol. 2002; 97: 104-8.
45. Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, Deng Y, Blennerhassett P et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 2011; 141: 599-609.
46. Verdú EF, Bercík P, Bergonzelli GE, Huang XX, Blennerhasset P, Rochat F, Fiaux M, Mansourian R et al. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 2004; 127: 826-37.
47. Dai C, Guandalini S, Zhao DH, Jiang M. Antinociceptive effect of VSL#3 on visceral hypersensitivity in a rat model of irritable bowel syndrome: a possible action through nitric oxide pathway and enhance barrier function. Mol Cell Biochem. 2012; 362: 43-53.
48. Johnson AC, Greenwood-Van Meerveld B, McRorie J. Effects of Bifidobacterium infantis 35624 on post-inflammatory visceral hypersensitivity in the rat. Dig Dis Sci. 2011; 56: 3179-86.
49. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome-a meta-analysis. Am J Gastroenterology 2006; 101: 1894-9.
50. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136: 1979-88.
51. Mai V, Braden CR, Heckendorf J, Pironis B, Hirshon JM. Monitoring of stool microbiota in subjects with diarrhea indicates distortions in composition. J Clin Microbiol 2006; 44: 4550-2.
52. Thabane M, Marshall JK. Post-infectious irritable bowel syndrome. World J Gastroenterology 2009; 15: 3591-6.
53. Schwille-Kiuntke J, Enck P, Zendler C, Krieg M, Polster AV, Klosterhalfen S, Autenrieth IB, Zipfel S et al. Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter. Neurogastroenterol Motil 2011; 23: 479-88.
54. Lee HR, Pimentel M. Bacteria and irritable bowel syndrome: the evidence for small intestinal bacterial overgrowth. Curr Gastroenterol Rep 2006; 8: 305-11.
55. Neal KR, Barker L, Spiller RC. Prognosis in post-infectious irritable bowel syndrome: a six year follow up study. Gut 2002; 51: 410-3.
56. Pimentel M, Chang C, Lembo A. Anti-vinculin antibodies: multicenter validation of diagnostic blood test for irritable bowel syndrome (IBS). Am J Gastroenterol. 2013; 108 (Suppl 1): A1887.
57. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011; 364: 22-32.
58. Pimentel M, Soffer EE, Chow EJ, Kong Y, Lin HC. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci. 2002; 47: 2639-43.
59. Pimentel M, Chow EJ. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 412-9.
60. Khoshini R, Dai SC. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 2008; 53: 1443-54.
61. Simrén M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut 2006; 55: 297-303.
62. Bye W, Ishaq N, Bolin TD, Duncombe VM, Riordan SM. Overgrowth of the indigenous gut microbiome and irritable bowel syndrome. World J Gastroenterol 2014; 20: 2449-55.
63. Spiegel BM. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. Clin Gastroenterol Hepatol. 2011; 9: 461-9.
64. Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G. The fecal microbial population in irritable bowel syndrome. Microbiologica 1982; 5: 185-94.
65. Si JM, Yu YC, Fan YJ, Chen SJ. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterology 2004; 10: 1802-5.
66. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33.
67. Kerckhoffs AP, Samsom M, van der Rest ME, de Vogel J, Knol J, Ben-Amor K, Akkermans LM. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterology 2009; 15: 2887-92.
68. Codling C, O'Mahony L, Shanahan F, Quigley EM, Marchesi JR. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci. 2010; 55: 392-7.
69. Rajilić-Stojanović M, Smidt H, de Vos WM. Diversity of the human gastrointestinal tract microbiota revisited. Environ Microbiol. 2007; 9: 2125-36.
70. Parkes GC, Brostoff J, Whelan K, Sanderson JD. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterology 2008; 103: 1557-67.
71. Rajilic-Stojanovic M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, deVos WM. Global and deep molecular analysis of microbiota signatures in fecal samplees from patients with irritable bowel syndrome. Gastroenterol 2011; 141: 1792-801.
72. Lyra A, Rinttila T, Nikkilä J, Krogius-Kurikka L, Kajander K, Malinen E, Mättö J, Mäkelä L et al. Diarrhoea- predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterology 2009; 15: 5936-45.
73. Parkes GC, Rayment NB, Hudspith BN, Petrovska L, Lomer MC, Brostoff J, Whelan K, Sanderson JD. Distinct microbial populations exist in the mucosa-associated microbiota of subgroups of irritable bowel syndrome. Neurogastroenterol Motil. 2012; 24: 31-9.
74. Jeffery IB, O'Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EM, Simrén M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61: 997-1006.
75. Vanhoutte T, Huys G, Brandt E, Swings J. Temporal stability analysis of the microbiota in human feces by denaturing gradient gel electrophoresis using universal and group-specific 16S rRNA gene primers. FEMS Microbiol Ecol 2004; 48: 437-46.
76. Matto J, Maunuksela L, Kajander K, Palva A, Korpela R, Kassinen A, Saarela M. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome-a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol. 2005; 43: 213-22.
77. Zoetendal EG, Akkermans AD, de Vos WM. Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol 1998; 64: 3854-9.
78. Caenepeel P, Janssens J, Vantrappen G, Eyssen H, Coremans G. Interdigestive myoelectric complex in germ-free rats. Dig Dis Sci 1989; 34: 1180-4.
79. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2009; 22: 512-e115.
80. Tazoe H, Otomo Y, Kaji I, Tanaka R, Karaki SI, Kuwahara A. Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. J Physiol Pharmacol 2008; 59 (Suppl 2): 251-62.
81. Fukumoto S, Tatewaki M, Yamada T, Fujimiya M, Mantyh C, Voss M, Eubanks S, Harris M et al. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1269-76.
82. Lee KJ, Tack J. Altered intestinal microbiota in irritable bowel syndrome. Neurogastroenterol Motil. 2010; 22: 493-8.
83. Chassard C, Dapoigny M, Scott KP, Crouzet L, Del'homme C, Marquet P, Martin JC, Pickering G et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther. 2012; 35: 828-38.
84. Matsunami M, Tarui T, Mitani K, Nagasawa K, Fukushima O, Okubo K, Yoshida S, Takemura M et al. Luminal hydrogen sulfide plays a pro-nociceptive role in mouse colon. Gut 2009; 58: 551-61.
85. Nakamura N, Lin HC, McSweeney CS, Mackie RI, Gaskins HR. Mechanisms of microbial hydrogen disposal in the human colon and implications for health and diseases. Annu Rev Food Sci Technol 2010; 1: 363-95.
86. Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, Park T, Stollman N, Rohlke F et al. Long-term follow-up of colonoscopic fecal microbiota transpla9t for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107: 1079-87.
87. Mattila E, Uusitalo-Seppälä R, Wuorela M, Lehtola L, Nurmi H, Ristikankare M, Moilanen V, Salminen K et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridiumdifficile infection. Gastroenterology 2012; 142: 490-6.
88. Aroniadis OC, Brandt LJ, Greenberg A. Long-term follow-up study of fecal microbiota transplantation for severe complicated Clostridium difficile infection. Gastroenterol 2013; 144: S185.
89. Brandt LJ, Aroniadis OC. Long-term follow-up study of fecal microbiota transplantation (FMT) for ulcerative colitis (UC) [abstract]. Am J Gastroenterol 2012; 1626: S657.
90. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012; 36: 503-16.
91. Borody TJ, George L, Andrews PJ. Bowel flora alteration: a potential cure of inflammatory bowel disease and irritable bowel syndrome? Med J Aust 1989; 150: 604.
92. Andrews P, Borody TJ, Shortis NP, Thompson S. Bacteriotherapy for chronic constipation - long term follow-up. Gastroenterology 1995; 108: A563.
93. Pinn D, Aroniadis O, Brandt LJ. Follow-up study of fecal microbiota transplantation (FMT) for the treatment of refractory irritable bowel syndrome (IBS). Am J Gastroenterol 2013; 108(Suppl 1s): S1862.
94. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes.Gastrointest Endosc 2013; 78: 240-9.
95. Borody TJ, Warren EF. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterology 2004; 38: 475-83.
96. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012; 107: 761-7.
97. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53: 994-1002.
98. Postigo R, Kim JH. Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis. Infection 2012; 40: 643-8.
99. Zipursky JS, Sidorsky TI, Freedman CA, Sidorsky MN, Kirkland KB. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis. 2012; 55:1652-8.
100. Landy J, Al-Hassi HO. Review article: faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther. 2011; 34: 409-15.
101. Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, Aroniadis O, Barto A et al. Fecal Microbiota Transplantation (FMT) for treatment of Clostridium difficile infection (CDI) in immunocompromised patients. Am J Gastroenterol. 2013; 108: S179.
102. Brandt LJ, Aroniadis OC, Greenberg A. Saftey of Fecal Microbiota Transplantation (FMT) in immunocompromised (Ic) patients with inflammatory bowel disease (IBD). Am J Gastroenterol. 2013. 108 [Suppl 1]: A1840.
103. Lagier JC. Fecal microbiota transplantation: from practices to legislation before considering industrialization. Clin Microbiol Infect. 2014. PMID 25273480. [Epub ahead of print]
104. National Institute for Health and Care Excellence. Faecal microbiota transplant for reccurent Clostridium difficile infection. 2014. http://www.nice.org.uk/guidance/ipg485
105. Petrof EO, Gloor GB, Vanner SJ, Weese SJ, Carter D, Daigneault MC, Brown EM, Schroeter K et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013; 1: 3.